Back to top
more

Catalyst Pharmaceuticals (CPRX)

(Delayed Data from NSDQ)

$21.24 USD

21.24
1,162,460

+0.08 (0.38%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $21.23 -0.01 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Y-mAbs (YMAB) Stock Up on Pre-BLA Meeting Completion With FDA

by Zacks Equity Research

Following a pre-BLA meeting with the FDA, Y-mAbs Therapeutics (YMAB) expects to resubmit its filing for omburtamabin CNS/leptomeningeal metastases from neuroblastoma by the end of first-quarter 2022.

Here's Why Momentum in Catalyst (CPRX) Should Keep going

by Zacks Equity Research

Catalyst (CPRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Wall Street Analysts See a 33% Upside in Catalyst (CPRX): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at a 33.3% upside potential for Catalyst (CPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Is Aravive (ARAV) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Aravive (ARAV) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.

Catalyst's (CPRX) Stock Up on 2022 Guidance for Firdapse

by Zacks Equity Research

Catalyst Pharmaceuticals (CPRX) reports preliminary sales figures for the fourth quarter. The company also provides its revenue guidance for 2022.

ChemoCentryx (CCXI) Gets Positive CHMP Opinion for Tavneos

by Zacks Equity Research

ChemoCentryx (CCXI) receives a positive recommendation from the CHMP for its lead drug Tavneos to treat two forms of ANCA-associated vasculitis.

How Much Upside is Left in Catalyst (CPRX)? Wall Street Analysts Think 30%

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 29.6% in Catalyst (CPRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Catalyst's (CPRX) Q3 Earnings In Line, Revenues Beat Estimates

by Zacks Equity Research

Catalyst's (CPRX) earnings meet estimates in the third quarter of 2021 while revenues beat the same.

Jazz Pharma (JAZZ) Q3 Earnings Beat, New Drugs Drive Sales

by Zacks Equity Research

Jazz Pharma's (JAZZ) product revenues grow in the third quarter on the back of strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals.

Catalyst Pharmaceutical (CPRX) Q3 Earnings Meet Estimates

by Zacks Equity Research

Catalyst (CPRX) delivered earnings and revenue surprises of 0.00% and 4.30%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Catalyst (CPRX) Is a Great Choice for "Trend" Investors, Here's Why

by Zacks Equity Research

Catalyst (CPRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Earnings Preview: Catalyst Pharmaceutical (CPRX) Q3 Earnings Expected to Decline

by Zacks Equity Research

Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Industry Outlook Highlights: Xencor, Enanta, Catalyst Pharmaceuticals, and Molecular Templates

by Zacks Equity Research

Zacks Industry Outlook Highlights: Xencor, Enanta, Catalyst Pharmaceuticals, and Molecular Templates

Kinjel Shah headshot

4 Small Drug Stocks That Hold Promise Despite Industry Challenges

by Kinjel Shah

Some residual impact of the coronavirus pandemic is expected on the Medical-Drugs industry players' third-quarter results. XNCR, ENTA, CPRX and MTEM may prove to be good additions to one's portfolio.

What Makes Catalyst (CPRX) a Good Fit for "Trend Investing"

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Catalyst (CPRX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Strength Seen in Catalyst (CPRX): Can Its 6.9% Jump Turn into More Strength?

by Zacks Equity Research

Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Why Is Catalyst (CPRX) Down 12.6% Since Last Earnings Report?

by Zacks Equity Research

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Catalyst (CPRX) Up More Than 20% in Past 3 Months: Here's Why

by Zacks Equity Research

Catalyst's (CPRX) lead drug, Firdapse, is approved for treating Lambert-Eaton myasthenic syndrome. The drug has seen solid uptake since its launch.

Catalyst (CPRX) Q2 Earnings Top Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Catalyst's (CPRX) earnings and revenues beat estimates in the second quarter of 2021. Shares inch up in after-hours trading.

Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Catalyst (CPRX) delivered earnings and revenue surprises of 77.78% and 16.37%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Catalyst Pharmaceutical (CPRX) Reports Next Week: What Awaits?

by Zacks Equity Research

Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Catalyst (CPRX) Thrives on Firdapse But Overdependence Concerns

by Zacks Equity Research

Catalyst's (CPRX) Firdapse is approved for treating Lambert-Eaton myasthenic syndrome. The drug has seen solid uptake since its launch. Sole dependence on Firdapse for growth remains a concern.

Catalyst (CPRX) Up 18.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Catalyst (CPRX) Q1 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Catalyst's (CPRX) earnings beat estimates in the first quarter of 2021 while revenues missed the same.

Catalyst Pharmaceutical (CPRX) Surpasses Q1 Earnings Estimates

by Zacks Equity Research

Catalyst (CPRX) delivered earnings and revenue surprises of 22.22% and -6.01%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?